From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona has a sizable and rapidly growing bioscience industry. State bioscience firms employed 25,686 in 2016 in 1,310 individual business establishments. Industry employment has grown by 9 percent since 2014, twice the growth rate of the nation, with four of the five major subsectors adding jobs during the period. Both drugs and pharmaceuticals and research, testing and medical labs have experienced double-digit job growth since 2014. Arizona inventors have been awarded nearly 2,000 bioscience-related patents since 2014, among the second quintile of states in patent activity. Since 2015, NIH awards to Arizona institutions have increased, reaching $189 million in FY 2017. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Handmade masks aim to preserve supply of personal protective equipment
Collaboration With FEMA Would Speed Delivery To Patients Where Needed Most
PHOENIX (March 23, 2020) – Medical toxicologists and emergency physicians are warning the public against the use of inappropriate medications and household products to prevent or treat COVID-19. In particular, Banner Health experts emphasize that chloroquine, a malaria medication, should not be ingested to treat or prevent this virus.
Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
Genentech will also provide 10,000 vials of Actemra to the U.S. Strategic National Stockpile Current U.S. supply of Actemra for approved indications is not expected to be impacted
- 1st Virtual Joint Meeting of the NCI Board of Scientific Advisors and the National Cancer Advisory Board
- Biopreneur Business Brief
- FDA Webinar - Clinical Laboratory Improvement Amendments (CLIA) Waiver Applications Final Guidances
- Fllinn Arizona's Bioscience Roadmap Progress Event
- AZBioPEERS: Fundraising Tales From The Road - Webcast